GlassScriptPhysician profile
Sarah Bell
NPI 1982352944
$1,726.46
in general payments reported to CMS, 2019-2025
20 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $396 · 2023: $404 · 2024: $422 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.45 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.57 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $301.64 | 2022-2025 | Rexulti |
| Abbvie INC. | $275.55 | 2022-2025 | |
| Novo Nordisk INC | $221.29 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $59.76 | 2022-2023 | Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $58.06 | 2024-2025 | Trintellix |
| Pfizer INC. | $52.64 | 2023-2024 | |
| Atricure, INC. | $49.43 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.25 | 2022-2023 | Xifaxan |
| Amgen INC. | $36.28 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.89 | 2022-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.62 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $26.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.07 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.14 | 2024 | Veozah |
| Dexcom, INC. | $19.56 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $18.92 | 2025 | Symbravo |
| Glaxosmithkline, LLC. | $14.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.